Insight Molecular Diagnostics Inc. SEC filings IMDX
Insight Molecular Diagnostics Inc. has 688 filings in SEC EDGAR's recent list, going back to May 14, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Nov 9, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 11, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 17, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Nov 12, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | Jul 29, 2020 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 12, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Nov 14, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | Aug 14, 2019 | Jun 30, 2019 |
| 10-Q | Quarterly report | May 14, 2019 | Mar 31, 2019 |
| 10-Q | Quarterly report | Nov 13, 2018 | Sep 30, 2018 |
| 10-Q | Quarterly report | Aug 14, 2018 | Jun 30, 2018 |
| 10-Q | Quarterly report | May 15, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Nov 14, 2017 | Sep 30, 2017 |
| 10-Q | Quarterly report | Aug 14, 2017 | Jun 30, 2017 |
| 10-Q | Quarterly report | Apr 28, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Nov 10, 2016 | Sep 30, 2016 |
| 10-Q | Quarterly report | Aug 11, 2016 | Jun 30, 2016 |
| 10-Q | Quarterly report | May 16, 2016 | Mar 31, 2016 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.